<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the optimal dose and timing of subcutaneous injection of insulin Aspart (IAsp) in relation to meal to mimic first phase insulin response in patients with recently diagnosed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: Twenty patients were randomised in a double blind, double dummy design to four standard meal tests with pre-meal injection of insulin Aspart 0.08 IU/kg BW 30 min before the meal, insulin Aspart 0.04 IU/kg BW 30 or 15 min before the meal and placebo </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> three insulin regimes significantly reduced postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> increment (area under the curve AUC(-30 to 240 min)) and peak plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> increment (DeltaC(max)) compared with placebo </plain></SENT>
<SENT sid="3" pm="."><plain>Postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> increment AUC(-30 to 240 min) but not DeltaC(max) was significantly lower with IAsp 0.08 IU/kg BW as compared to IAsp 0.04IU/kg BW, (p&lt;0.03 and p=0.18) </plain></SENT>
<SENT sid="4" pm="."><plain>One patient experienced <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> after injection of IAsp 0.08 IU/kg BW </plain></SENT>
<SENT sid="5" pm="."><plain>No difference in postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> profile was demonstrated whether IAsp 0.04 IU/kg BW was administrated 15 or 30 min before mealtime </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: IAsp 0.04IU/kg BW injected subcutaneously 15 or 30 min before meal reduced the postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> increment without risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> in patients with recently diagnosed type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>Doubling of the IAsp dose significantly reduced the postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> increment but increased the risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
</text></document>